Effect of Repeated Doses of YF476 on Stomach Acidity

This study has been completed.
Sponsor:
Collaborator:
James Black Foundation
Information provided by (Responsible Party):
Trio Medicines Ltd.
ClinicalTrials.gov Identifier:
NCT01601405
First received: May 16, 2012
Last updated: NA
Last verified: May 2012
History: No changes posted
  Purpose

The objectives of the study were:

  1. To show that a single dose of YF476 blocks gastrin receptors in healthy subjects
  2. To show that YF476 retains its ability to block gastrin receptors after repeated dosing despite losing its ability to suppress gastric acidity.

Condition Intervention Phase
Hypergastrinaemia
Drug: YF476
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Open Study of the Effect of Repeated Doses of YF476 on Pentagastrin-induced Gastric Acid Output in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Trio Medicines Ltd.:

Primary Outcome Measures:
  • Safety of YF476 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    Assessed by by physical examinations, safety tests of blood and urine, ECG variables

  • Tolerability of YF476 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    Assessed by adverse events

  • Pharmacokinetic analysis of plasma YF476 concentrations [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    On Study Days 1 and 7, blood samples taken at 90 and 210 minutes after the start of gastric aspiration. On Study Day 14, a blood sample taken at 90 minutes only. Plasma separated and stored for subsequent assay of YF476, if deemed necessary.

  • Pharmacodynamic measurement for assay of volume, pH and total acidity of gastric aspirate [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

    On Study Days 0, 1, 7 & 14:

    volume, pH and total acidity of gastric aspirate measured at 15-min intervals from 0-30 & 90-210 min after the start of gastric aspiration


  • Pharmacodynamic measurement for assay of pancreastatin and pancreatic polypeptides [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

    On Study Days 0, 1, 7 & 14:

    blood samples taken at about -30 min before the start of gastric aspiration, just before the introduction of nasogastric tube. Serum separated and stored for subsequent assay of pancreastatin, pancreatic polypeptide, and any other gastro-intestinal hormone (if necessary)


  • Pharmacodynamic measurement for assay of gastrin [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

    On Study Days 0, 1, 7 & 14:

    blood samples taken at 90 min after the start of gastric aspiration. Serum separated and stored for subsequent assay of gastrin, if necessary



Enrollment: 10
Study Start Date: October 2001
Study Completion Date: November 2001
Primary Completion Date: November 2001 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: YF476
    Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
    Drug: Placebo
    On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
Detailed Description:

The rationale for this study was as follows.

On the basis of the pre-clinical studies, the original target disease for YF476 was gastro-oesophageal reflux disease (GORD), not only because of the excellent anti-secretory activity of YF476 but also because of its potential for increasing gastric emptying. But loss of the anti-secretory effect of YF476 in healthy subjects after repeated dosing excludes its use as an anti-secretory agent in patients with GORD. However, there is some evidence from within our repeated-dose studies in healthy subjects that gastrin receptors are blocked despite loss of the anti-secretory activity of YF476. Further evidence that repeated doses of YF476 cause sustained blockade of gastrin receptors comes from several types of study in animals. First, in the 13-week toxicology studies, all dose levels of YF476 reduced the ECL population, unlike other anti-secretory agents, histamine H2-antagonists and proton-pump inhibitors, which increase the ECL population. Second, YF476 at doses of 0.1 and 1.0 mg/kg subcutaneously twice daily for 14 days in rats abolished the increase in gastric output induced by pentagastrin on Days 1, 7 and 14.

This protocol describes a study in healthy subjects using inhibition of pentagastrin-induced gastric acid output as a surrogate marker of efficacy of YF476. Pentagastrin has been used for many years to test gastric function in healthy subjects and patients. Intravenous infusion of 0.6 micrograms/kg/hour is a submaximal and well-tolerated dose.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or female volunteers.
  • Aged 18-45 years.
  • A body mass index (Quetelet index) in the range 18.0-30.9.
  • Women at risk of pregnancy must use a reliable method of contraception.
  • No clinically relevant abnormal findings in the clinical history or physical examination at the screening assessment which could interfere with the objectives of the study or make the volunteer's participation hazardous.
  • No clinically relevant abnormal laboratory values at the screening evaluation, including a normal ECG.
  • Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.
  • Willingness to give written consent to participate after reading the Consent Form, and after having the opportunity to discuss the study with an investigator or his deputy.

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the volunteer.
  • Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the study or make it unnecessarily hazardous.
  • Positive test for Helicobacter pylori.
  • Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
  • Presence or history of severe adverse reaction to any drug or a history of severe allergic disease.
  • Use of a prescription medicine (except oral contraceptives in females) during the 30 days before the study or use of an over-the-counter medication, with the exception of paracetamol, during the 7 days before the study.
  • Participation in other clinical studies of a new chemical entity or a prescription medicine within the previous 3 months.
  • Smokers.
  • Presence or history of drug or alcohol abuse, or intake of more than 28 units of alcohol weekly (for men) or 21 units of alcohol weekly (for women).
  • Blood pressure and heart rate in seated position at the screening examination outside the ranges 90-160 mm Hg systolic, 40-95 mm Hg diastolic; heart rate 40_100 beats/min.
  • Possibility that the volunteer will not cooperate with the requirements of the protocol.
  • Evidence of drug abuse on urine testing.
  • Positive test for hepatitis B, hepatitis C, HIV1 or HIV2.
  • Loss of more than 400 mL blood during the 3 months before the study, e.g. as a blood donor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01601405

Locations
United Kingdom
Hammersmith Medicines Research
London, United Kingdom
Sponsors and Collaborators
Trio Medicines Ltd.
James Black Foundation
Investigators
Study Director: Malcolm Boyce Trio Medicines Limited
  More Information

No publications provided

Responsible Party: Trio Medicines Ltd.
ClinicalTrials.gov Identifier: NCT01601405     History of Changes
Other Study ID Numbers: 01-023
Study First Received: May 16, 2012
Last Updated: May 16, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Trio Medicines Ltd.:
YF476
gastrin receptor antagonist
gastrin
gastric aspiration
healthy subjects

ClinicalTrials.gov processed this record on September 22, 2014